A gene therapy’s path from the research lab to the clinic and, ultimately, the market requires manufacturing processes that will meet the regulatory requirements and logistics to get therapies to clinical trial sites.
Improve the characterization of cell-based AAV transfection and production, increase the efficiency and accuracy of both processes, and shorten development time.
Accelerated clinical trial timelines for advanced therapeutics are on the rise. With Fast Track designations, it is increasingly critical for innovators to have efficient and scalable production processes.
Hear about Catalent's venture into the development and manufacturing of viral vector gene therapies and how we are overcoming challenges and maintaining our commitment to our partners.
This website uses cookies to ensure you get the best experience on our website. Learn more
